Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 166.39
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2010, vol. 19, nr 3, May-June, p. 379–387

Publication type: review article

Language: English

The Role of Thrombin-Activatable Fibrinolysis Inhibitor in the Pathophysiology of Hemostasis

Rola inhibitora fibrynolizy aktywowanego trombiną w patofizjologii hemostazy

Joanna Dubis1,, Wojciech Witkiewicz1,

1 Regional Specialist Hospital in Wrocław, Research and Development Center, Poland

Abstract

The fibrinolytic system is responsible for the enzymatic degradation of fibrin and participates in a wide variety of physiological and pathological processes, such as hemostatic balance, tumor invasion, angiogenesis, tissue remodeling, and reproduction. The balance between clot formation and fibrinolysis is controlled by the molecular components of the hemostatic system, including thrombin-activatable fibrinolysis inhibitor (TAFI). Several studies indicate an important role for plasma TAFI in the regulation of fibrinolysis. It is activated by thrombin during blood clotting and is a link between coagulation and fibrinolysis. Moreover, TAFI plays a pivotal role in inflammation. In this review, recent basic and clinical findings that demonstrate the role of TAFI in regulating the crosstalk between coagulation, fibrinolysis, and inflammation are summarized.

Streszczenie

Układ fibrynolizy jest odpowiedzialny za enzymatyczną degradację fibryny, a także uczestniczy w wielu procesach fizjologicznych i patologicznych, takich jak: hemostaza, migracja komórek nowotworowych, angiogeneza, przebudowa tkanek, rozród. Równowaga między procesem powstawania skrzepu a fibrynolizą jest precyzyjnie kontrolowana przez czynniki układu hemostazy, w tym przez inhibitor fibrynolizy aktywowany trombiną (TAFI). Wykazano, że osoczowe stężenie TAFI ma znaczący wpływ na proces fibrynolizy w stanach patologicznych. Inhibitor TAFI jest aktywowany przez trombinę i jest czynnikiem wiążącym między procesem koagulacyjnym a fibrynolizą. TAFI pełni także ważną rolę w procesie zapalenia. W pracy przedstawiono najnowsze wyniki badań podstawowych i klinicznych na temat roli TAFI w regulacji powiązań między procesami krzepnięcia krwi, fibrynolizy i zapalenia.

Key words

thrombin-activatable fibrinolysis inhibitor, hemostasis

Słowa kluczowe

inhibitor fibrynolizy aktywowany trombiną, hemostaza

References (46)

  1. Zorio E, Gilabert-Estellés J, España F, Ramón LA, Cosín R, Estellés A: Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem 2008, 5, 923–929.
  2. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL: The cell biology of the plasminogen system. FASEB J 1995, 9, 939–945.
  3. Fleury V, Anglés-Cano E: Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxyterminal lysines. Biochemistry 1991, 30, 7630–7638.
  4. Mosnier LO, Meijers JC, Bouma BN: Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001, 85, 5–11.
  5. Wang YX, da Cunha V, Vincelette J, Zhao L, Nagashima M, Kawai K, Yuan S, Emayan K, Islam I, Hosoya J, Sullivan ME, Dole WP, Morser J, Buckman BO, Vergona R: A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) – part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost 2007, 97, 54–61.
  6. Bajzar L, Manuel R, Nesheim ME: Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995, 270, 14477–14484.
  7. Mosnier LO, Buijtenhuijs P, Marx PF, Meijers JC, Bouma BN: Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003, 101, 4844–4846.
  8. Campbell WD, Lazoura E, Okada N, Okada H: Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002, 46, 131–134.
  9. Tilburg NH, Rosendaal FR, Bertina RM: Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000, 95, 2855–2859.
  10. Tregouet DA, Schnabel R, Alessi MC, Godefroy T, Declerck PJ, Nicaud V, Munzel T, Bickel C, Rupprecht HJ, Lubos E, Zeller T, Juhan-Vague I, Blankenberg S, Tiret L, Morange PE: AtheroGene Investigators. Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arterioscler Thromb Vasc Biol 2002, 22, 867–873.
  11. Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H: Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 2001, 104, 1–6.
  12. Bajzar L, Morser J, Nesheim M: TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996, 271, 16603–16608.
  13. Bouma BN, Meijers JC: Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U) Thromb Haemost 2003, 1, 1566–1574.
  14. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M: Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002, 11, 277, 1021–1030.
  15. Boffa MB, Bell R, Stevens WK, Nesheim ME: Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 2000,275, 12868–12878.
  16. Vairaktaris E, Yapijakis C, Nkenke E, Vassiliou S, Vylliotis A, Nixon AM, Derka S, Ragos V, Spyridonidou S, Tsigris C, Neukam FW, Patsouris E: The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer. Am J Hematol 2007, 82, 1010–1012.
  17. Campbell W, Okada H: An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989, 162, 933–939.
  18. Mutch NJ, Moore NR, Wang E, Booth NA: Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J Thromb Haemost 2003, 1, 2000–2007.
  19. Mosnier LO, Bouma BN: Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 2006, 26, 2445–2453.
  20. Colucci M, Cattaneo M, Martinelli I, Semeraro F, Binetti BM, Semeraro N: Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential. J Thromb Haemost 2008, 6, 1571–1577.
  21. Lorand L: Sol Sherry Lecture in Thrombosis: research on clot stabilization provides clues for improving thrombolytic therapies. 1: Arterioscler Thromb Vasc Biol 2000, 20, 2–9.
  22. Vairaktaris E, Yapijakis C, Nkenke E, Vassiliou S, Vylliotis A, Nixon AM, Derka S, Ragos V, Spyridonidou S, Tsigris C, Neukam FW, Patsouris E: The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer. Am J Hematol 2007, 82, 1010–1012
  23. Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, Juhan-Vague I: Identification of polymorphisms in the promoter and the 3’ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001, 97, 2053–2058.
  24. Morange PE, Tregouet DA, Frere C, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Cambien F, Tiret L, Juhan-Vague I: The Prime Study Group. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. J Thromb Haemost 2005, 3, 1503–1510.
  25. Martini CH, Brandts A, de Bruijne EL, van Hylckama Vlieg A, Leebeek FW, Lisman T, Rosendaal FR: The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol 2006, 134, 92–94.
  26. Akatsu H, Ishiguro M, Ogawa N, Kanesaka T, Okada N, Yamamoto T, Campbell W, Okada H: Plasma levels of unactivated thrombin activatable fibrinolysis inhibitor (TAFI) are down-regulated in young adult women: analysis of a normal Japanese population. Microbiol Immunol 2007, 51, 507–517.
  27. Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, Pearl RG, Leung LL: Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003, 278, 51059–51067.
  28. Boffa MB, Hamill JD, Maret D, Brown D, Scott ML, Nesheim ME, Koschinsky MLJ: Acute Phase Mediators Modulate Thrombin-activable Fibrinolysis Inhibitor (TAFI) Gene Expression in HepG2 Cells. Biol Chem 2003, 278, 9250–9257.
  29. Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A: Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 2003, 122(6), 958–965.
  30. Okumura N, Koh T, Hasebe Y, Seki T, Ariga T: A novel function of thrombin-activatable fibrinolysis inhibitor during rat liver regeneration and in growth-promoted hepatocytes in primary culture. J Biol Chem 2009, 284, 16553–16561.
  31. Donmez A, Aksu K, Celik HA, Keser G, Cagirgan S, Omay SB, Inal V, Aydin HH, Tombuloglu M, Doganavsargil E: Thrombin activatable fibrinolysis inhibitor in Behçet’s disease. Thromb Res 2005, 115, 287–292.
  32. Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA: Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2008, 20, 912–916.
  33. Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S: Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients. Endocr J 2007, 54, 593–599.
  34. Gresele P, Binetti BM, Branca G, Clerici C, Asciutti S, Morelli A, Semeraro N, Colucci M: TAFI deficiency in liver cirrhosis: relation with plasma fibrinolysis and survival. Thromb Res 2008, 121, 763–768.
  35. Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N, Meier B, Kohler HP: Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 2002, 88, 1020–1025.
  36. Montaner J, Ribó M, Monasterio J, Molina CA, Alvarez-Sabín J: Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 2000, 34, 1038–1040.
  37. Franco RF, Reitsma PH: Genetic risk factors of venous thrombosis. Hum Genet 2001, 109, 369–384.
  38. Wang X, Smith PL, Hsu MY, Tamasi JA, Bird E, Schumacher WA: Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis. J Thromb Thrombolysis 2007, 23, 41–49.
  39. Ricart JM, Ramón LA, Vayá A, España F, Santaolaria ML, Todolí J, Castelló R, Fontcuberta J, Estellés A: Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis. Br J Haematol 2008, 141, 716–719.
  40. Emonts M, de Bruijne EL, Guimarães AH, Declerck PJ, Leebeek FW, de Maat MP, Rijken DC, Hazelzet JA, Gils A: Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. 1: J Thromb Haemost 2008, 6, 268–276.
  41. Letai A, Kuter DJ: Cancer, coagulation, and anticoagulation. Oncologist 1999, 4, 443–449.
  42. Reijerkerk A, Meijers JC, Havik SR, Bouma BN, Voest EE, Gebbink MF: Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice. J Thromb Haemost 2004, 2, 769–779.
  43. Hataji O, Taguchi O, Gabazza EC, Yuda H, D’Alessandro-Gabazza CN, Fujimoto H, Nishii Y, Hayashi T, Suzuki K, Adachi Y: Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients. Am J Hematol 2004, 76, 214–219.
  44. Koldas M, Gummus M, Seker M, Seval H, Hulya K, Dane F, Kural A, Gumus A, Salepci T, Turhal NS: Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer. Clin Lung Cancer 2008, 9, 112–115.
  45. Meijers JC, Oudijk EJ, Mosnier LO, Bos R, Bouma BN, Nieuwenhuis HK, Fijnheer R: Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 2000, 108, 518–523.
  46. Lansberg MG, Bluhmki E, Thijs VN: Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke 2009, 40, 2438–2441.